Brought to you by 
EsbaTech brings in €32mm in Series B round; adds €14mm
18 Sep 2009
Executive Summary
EsbaTech AG (develops antibody fragment therapeutics for Alzheimer's disease, cancer, and inflammation) raised €32mm ($41mm) in its Series B recapitalization financing round. New investors SV Life Sciences, Clarus Ventures, HBM BioVentures, and HBM BioCapital were joined by existing backers Novartis Venture Fund, BioMedinvest, and Venture Incubator (VI) Partners.
Deal Industry
- Pharmaceuticals
- Research, Analytical Equipment & Supplies
-
Biotechnology
-
Large Molecule
- Antibodies
-
Drug Discovery Tools
- Genomics-Proteomics
-
Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
EsbaTech brings in €32mm in Series B round; adds €14mm
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice